Threshold is a biotechnology company focused on the discovery and development of therapeutics that selectively target Tumor Hypoxia, a property of solid tumors and some hematologic cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.
Our lead compound TH-302 has been tested in more than 330 patients and has demonstrated positive responses in a broad variety of tumors.Learn More About TH-302
Register to learn more about our pipeline and clinical advances and to download the company fact sheet.
% Change -1.60%